| |
| | Profile |
 | | Mick R, Crowley J, Cassady RJ, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Control Clin Trials, 21(4), 343-359, 2000 |
 | | Gooley TA, Leisenring W, Crowley J, et al, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, 18, 695-706, 1999 |
 | | Crowley J, LeBlanc M, Jacobson J, Salmon S, Some exploratory tools for survival analysis, Lecture Notes in Statistics. |
| myprofile.cos.com /crowleyj94 (356 words) |
|